Last reviewed · How we verify
Investigational 23-valent PPV
A 23-valent pneumococcal polysaccharide vaccine that stimulates the immune system to produce antibodies against 23 serotypes of Streptococcus pneumoniae.
A 23-valent pneumococcal polysaccharide vaccine that stimulates the immune system to produce antibodies against 23 serotypes of Streptococcus pneumoniae. Used for Prevention of invasive pneumococcal disease and pneumococcal pneumonia in adults and children.
At a glance
| Generic name | Investigational 23-valent PPV |
|---|---|
| Sponsor | Sinovac Biotech Co., Ltd |
| Drug class | Pneumococcal polysaccharide vaccine |
| Target | Streptococcus pneumoniae capsular polysaccharides (23 serotypes) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains purified capsular polysaccharides from 23 different serotypes of pneumococcus conjugated or presented to elicit a humoral immune response. This induces B-cell activation and antibody production (primarily IgG) that provides protection against invasive pneumococcal disease and pneumococcal pneumonia caused by the included serotypes. As a polysaccharide vaccine, it primarily activates T-cell-independent B-cell responses.
Approved indications
- Prevention of invasive pneumococcal disease and pneumococcal pneumonia in adults and children
Common side effects
- Injection site pain, erythema, or swelling
- Fever
- Myalgia or arthralgia
- Headache
Key clinical trials
- Immunogenicity and Safety of 23-valent Pneumococcal Polysaccharide Vaccine (PHASE4)
- A Clinical Trial of 23-valent Pneumococcal Polysaccharide Vaccine (PHASE4)
- Safety and Immunogenicity Study of 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Children, Adults and Elderly (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Investigational 23-valent PPV CI brief — competitive landscape report
- Investigational 23-valent PPV updates RSS · CI watch RSS
- Sinovac Biotech Co., Ltd portfolio CI